Cost and management of asthma exacerbations in Spanish hospitals (COAX study in hospital services);Coste y manejo de una crisis asmática en el ámbito hospitalario de nuestro medio (estudio COAX en servicios hospitalarios)

Archivos de Bronconeumologia

Volumn 41, Issue 6, 2005, Pages 313-321

  Borderias Clau L ^a   Zabaleta Murguionda, M ^b   Riesco Miranda, J A ^c   Pellicer Ciscar, C ^d   Hernandez Hernandez J R ^e   Carrillo Diaz T ^f   Lumbreras Garcia G ^g  

^a HOSPITAL SAN JORGE   (Spain)

^b HOSPITAL DE LAREDO   (Spain)

^c HOSPITAL VIRGEN DEL PUERTO   (Spain)

^d F Borja Hospital   (Spain)

^e HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^f HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^g Centro de Salud   (Spain)

Author keywords

Asthma; Asthma exacerbation; Hospital care; Resource management

Indexed keywords

ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OXYGEN; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; EUROPE; FEMALE; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEBULIZER; OXYGEN THERAPY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION;

EID: 22544461943     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13075999     Document Type: Article

References (32)

1. Global Strategy for Asthma management and prevention. NHL-BI/WHO Workshop Report. Bethesda: National Institute of Health, 1998 [publication n.° 96-3659B].
2. Jönsson B. Measuring the economic burden in asthma. En: Weiss KB, Buist AS, Sullivan SD, editors. Asthma's impact on society. The social and economic burden. New York: Marcell Dekker Inc; 2000. p. 251-68.
3. Plaza Moral V. Farmacoeconomía del asma. Arch Bronconeumol. 1999;35 Supl 3:22-6.
4. Serra-Batlles J, Plaza V, Morejón E, Cornelia A, Brugués J. Cost of asthma according to the degree of severity. Eur Respir J. 1998;12:1322-6.
5. Barnes PJ, Jönsson B, Klim JB. The cost of asthma. Eur Respir J. 1996;9:636-42.
6. Gibson PG. Monitoring the patient with asthma: an evidence-based approach. J Allergy Clin Inmunol. 2000;106:17-26.
7. Bousquet J. A physician's view of health economics in asthma. Eur Respir Rev. 1995;5:275-8.
8. Gergen PJ. Understanding the economic burden of asthma. J Allergy Clin Immunol. 2001;107 Supl 5:445-8.
9. a ed. Madrid: Díaz de Santos; 2000.
10. Olm Font M. Diccionario básico de gestión. Madrid: Ergón; 2000.
11. Consejo General de Colegios Ofïciales de Farmacéuticos. Catálogo de especialidades farmacéuticas 1999. Madrid: CGCOF; 1999.
12. Gisbert R, Brosa M. Base de datos de costes sanitarios v. 1.3 [en CD-ROM]. Barcelona: Centro de Estudios en Economía de la Salud y de Política Social (SOIKOS); 2000.
13. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economies. 1998;7:723-40.
14. Weiss KB, Sullivan SD. The health economics of asthma. En: Busse WW, Holgate S, editors. Asthma and rhinitis. 2nd ed. Cambridge: Blackwell Scientific; 2000. p. 1786-92.
15. Jatulis D, Meng Y, Elashoff R, Schocket AL, Raeburn ME, Hasan AG, et al. Preventive pharmacologic therapy among asthmatics: five years after the publication of guidelines. Ann Allergy Asthma Immunol. 1998;81:82-8.
16. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16:802-7.
17. López-Viña A, Cimas JE, Díaz C, Coria G, Vegazo O, Picado C. A comparison of primary care physician and pneumologists in the management of asthma in Spain: ASES study. Respir Med. 2003;97:872-81.
18. Plaza V, Serrano J, Picado C, Sanchís J, on behalf of the High Risk Asthma Research Group. Frequency and clinical characteristics of rapid -onset fatal and near fatal asthma. Eur Respir J. 2002;19:846-52.
19. Picado C. Classification of severe asthma exacerbations: a proposal. Eur Respir J. 1996;9:1775-8.
20. Godard P, Chánez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1 yr prospective study. Eur Respir J. 2002;19:61-7.
21. Schwenkglenks M, Lowy A, Anderhub H, Szucs T. Costs of asthma in a cohort of Swiss adults: associations with exacerbation status and severity. Value Health. 2003;6:75-83.
22. Cisternas M, Blanc PD, Yen IH, Katz P, Earnest G, Eisner M, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111:1212-8.
23. Smith DH, Malone DC, Lawson K, Okamoto L, Battista C, Saunders W. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997;156:787-93.
24. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and cost associated with asthma attack. Thorax. 2000;55:19-24.
25. Balkrishnan R, Norwood J, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients. Clin Ther. 1998;20:567-80.
26. Ozminkowski RJ, Wang S, Marder WD, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. Pharmaeconomics. 2000;18:253-64.
27. Bolton MB, Tilley BC, Kuder J, Reeves T, Schultz LR. The cost and effectiveness of an education program for adults who have asthma. J Gen Int Med. 1991;6:401-7.
28. Sondergaard B, Davidsen F, Kirkeby B, Rasmussen M, Hey H. The economics of an intensive education programme of asthmatic patients: a prospective controlled trial. Pharmacoeconomics. 1992;1:207-12.
29. Gallefoss F, Bakke PS. Cost-effectiveness of self-management in asthmatics: a 1-yr follow-up randomised, controlled trial. Eur Respir J. 2001;17:206-13.
30. Pauley T, Magee MJ, Cury JD. Pharmacist-managed, physician-directed asthma management program reduces emergency department visits. Ann Pharmacother. 1995;29:5-9.
31. Van Ganse E, Laforest L, Pietri G, Boissel JP, Gormand F, Ben Joseph R, et al. Persistent asthma: disease control, resource utilization and direct costs. Eur Respir J. 2002;20:260-7.
32. Lane S, Borderías L, Plusa T, Kleech M. Secondary care costs of managing asthma exacerbations: results of a survey in five Eastern European countries and three EU countries. Actas de ATS International Conference; Orlando; 2004;A360:póster A27